Literature DB >> 22445108

Laparoscopic myomectomy in peri- and post-menopausal women is safe, efficacious and associated with long-term patient satisfaction.

Marc P Radosa1, Harald Winzer, Anke R Mothes, Oumar Camara, Herbert Diebolder, Anja Weisheit, Ingo B Runnebaum.   

Abstract

OBJECTIVE: Women in the peri- and post-menopause may ask for uterus-preserving therapy options when presenting with benign uterine disorders such as symptomatic fibroids. Laparoscopic myomectomy (LM) for patients in the peri- and post-menopause as a surgical alternative to hysterectomy is widely considered to be non-standard treatment. The aim of this study was to analyze safety and outcome of LM beyond the reproductive period. STUDY
DESIGN: We evaluated the surgical outcome and patient satisfaction for a total of 451 patients: 85 peri- or post-menopausal women as group A and, for reference, 366 premenopausal women in group B, who received LM from 1998 to 2008 in our department. We analyzed data from our medical records and applied a patient questionnaire in September 2009.
RESULTS: The average number of fibroids removed and size of the leading fibroid were similar in both groups. Time of surgery was different in group A, at 102.8 min, compared to group B, 128.6 min (p<0.01). Rates of intra- (2.21% overall) and post-operative complications (6.22% overall) were comparable for both groups. Post-surgical hospitalization was shorter in group B (4.4 days) compared to group A (5.0 days) (p<0.01). Evaluation of the questionnaire showed high satisfaction with the results of LM in both subgroups with a significantly lower number of relapses in group A (3.5%) compared to group B (11.2%).
CONCLUSION: Laparoscopic myomectomy as a surgical treatment option in the peri- and post-menopause was characterized by a low rate of complications and relapses as well as a high degree of patient satisfaction in our analysis.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22445108     DOI: 10.1016/j.ejogrb.2012.02.024

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

1.  Standardised Registration of Surgical Complications in Laparoscopic-Gynaecological Therapeutic Procedures Using the Clavien-Dindo Classification.

Authors:  M P Radosa; G Meyberg-Solomayer; J Radosa; J Vorwergk; K Oettler; A Mothes; S Baum; I Juhasz-Boess; E Petri; E F Solomayer; I B Runnebaum
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-08       Impact factor: 2.915

2.  Influence of the Preoperative Decision-Making Process on the Postoperative Outcome after Hysterectomy for Benign Uterine Pathologies.

Authors:  J C Radosa; C G Radosa; C Kastl; R Mavrova; L Gabriel; S Gräber; G Wagenpfeil; S Baum; A Hamza; R Joukhadar; I Juhasz-Böss; A-S Heimes; G Meyberg-Solomayer; E-F Solomayer; M P Radosa
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-04       Impact factor: 2.915

3.  Postoperative Quality of Life and Sexual Function in Premenopausal Women Undergoing Laparoscopic Myomectomy for Symptomatic Fibroids: A Prospective Observational Cohort Study.

Authors:  Julia Caroline Radosa; Christoph Georg Radosa; Russalina Mavrova; Stefan Wagenpfeil; Amr Hamza; Ralf Joukhadar; Sascha Baum; Maria Karsten; Ingolf Juhasz-Boess; Erich-Franz Solomayer; Marc Philipp Radosa
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

4.  Use of a microsurgical vascular clip system (Yasargil clip) in laparoscopic fibroid enucleation

Authors:  Shadi Younes; Julia Caroline Radosa; Anke Mothes; Bahriye Aktaş; Marc Philipp Radosa
Journal:  J Turk Ger Gynecol Assoc       Date:  2020-06-05

5.  Use of a microsurgical vascular clip system for temporary bilateral occlusion of the four main uterine vessels for laparoscopic enucleation of very large intramural uterine fibroids.

Authors:  Shadi Younes; Marc Radosa; Achim Schneider; Julia Radosa; Alexey Eichenwald; Christiane Weisgerber; Bahriye Aktas
Journal:  Arch Gynecol Obstet       Date:  2022-07-27       Impact factor: 2.493

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.